Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 11/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etofylline SCHEMBL149271 | 0.89 | ADORA2B (1.00) | ADORA2BLMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL16120984 | 0.88 | ADORA2B (0.81) | ADORA2BLMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL19533057 | 0.86 | ADORA2B (0.73) | ADORA2BLMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL9293406 | 0.86 | ADORA2B (0.83) | ADORA2BLMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL16120979 | 0.85 | ADORA2B (0.85) | ADORA2BLMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL516014 | 0.85 | ADORA2B (0.72) | ADORA2BLMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL16120975 | 0.85 | ADORA2B (0.88) | ADORA2BLMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL19370573 | 0.85 | ADORA2B (0.71) | ADORA2BLMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL8697228 | 0.84 | ADORA2B (0.81) | ADORA2BLMNAMAPTSMN1; SMN2POLB | |
| SCHEMBL8666393 | 0.83 | ADORA2B (0.79) | ADORA2BLMNAMAPTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | claimed |
| EP-0502043-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR. | LVMH RECH (FR) | 1992-09-09 | — | — | EP | claimed |
| WO-1991007945-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECHERCHE (FR) | 1991-06-13 | — | — | WO | claimed |
| US-9649381-B2 | Transporter protein-coupled nanodevices for targeted drug delivery | WAYNE STATE UNIVERSITY (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150125926-A1 | TRANSPORTER PROTEIN-COUPLED NANODEVICES FOR TARGETED DRUG DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-07 | — | — | US | disclosed |
| EP-1904020-A2 | NEW SLIMMING COSMETIC COMPOSITIONS | Sederma S.A.S. (FR) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007010478-A2 | SLIMMING COSMETIC COMPOSITIONS | SEDERMA (FR) | 2007-01-25 | — | — | WO | disclosed |
| US-5470579-A | Xanthines, optionally incorporated in liposomes, for promoting skin or hair pigmentation | LVMH, RECHERCHE (FR) | 1995-11-28 | — | — | US | disclosed |
| EP-0502043-B1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECH (FR) | 1995-03-01 | — | — | EP | disclosed |
| EP-0502043-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR. | LVMH RECH (FR) | 1992-09-09 | — | — | EP | disclosed |
| WO-1991007945-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECHERCHE (FR) | 1991-06-13 | — | — | WO | disclosed |
| WO-1990008128-A1 | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS | BUNDGAARD HANS (DK) | 1990-07-26 | — | — | WO | disclosed |
| US-4845081-A | PRODRUGS, URACILS | UNIVERSITY OF FLORIDA (US) | 1989-07-04 | — | — | US | disclosed |
| EP-0189101-A3 | COMPOUNDS HAVING MUCOLYTIC AND BRONCHODILATING ACTIVITY, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM AS ACTIVE PRINCIPLE | PROTER S.p.A. (IT) | 1987-10-14 | — | — | EP | disclosed |
| US-4614811-A | REACTING BARIUM SALT OF AMINOMALONIC ACID WITH PLATINUM SULFATE AMINO INTERMEDIATE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1986-09-30 | — | — | US | disclosed |
| EP-0189101-A2 | Compounds having mucolytic and bronchodilating activity, a process for their preparation and pharmaceutical composition containing them as active principle | PROTER S.p.A. (IT) | 1986-07-30 | — | — | EP | disclosed |
| EP-0189101-A2 | Compounds having mucolytic and bronchodilating activity, a process for their preparation and pharmaceutical composition containing them as active principle | PROTER S.p.A. (IT) | 1986-07-30 | — | — | EP | disclosed |
| US-4275064-A | Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents | INTERX RESEARCH CORPORATION (US) | 1981-06-23 | — | — | US | disclosed |
| US-4061753-A | Treating psoriasis with transient pro-drug forms of xanthine derivatives | INTERX RESEARCH CORPORATION (US) | 1977-12-06 | — | — | US | disclosed |
| US-4045567-A | 2-Alkyl-5-thiazole-carboxylic acid derivatives in hypolipemiant compositions | ROUSSEL UCLAF (FR) | 1977-08-30 | — | — | US | disclosed |